Pseudobulbar Affect: Emotional Lability in Neurodegenerative Diseases Symposium Brings Debilitation Neurological Condition into Focus

San Diego, October 8, 2003 – Dr. Matthew B. Stern of the Penn Neurologic Institute and Dr. John Trojanowski of the Institute on Aging and the Center for Neurodegenerative Disease Research of the University of Pennsylvania Medical Center will co-chair an educational symposium on pseudobulbar affect today. The Continuing Medical Education (CME) certified symposium will provide physicians and other healthcare professionals with an increased awareness and understanding of pseudobulbar affect (PBA) and emotional lability in neurodegenerative diseases.

Approximately 120 neurologists, psychiatrists, geriatricians, trauma physicians, internists and family practice specialists and health care professionals will attend the program being held on Wednesday, October 8th at the Inn at Penn in Philadelphia, Pennsylvania.

“PBA is a debilitating consequence of several common and rare neurological disorders and more effective therapeutic interventions are needed to treat this,” noted Dr. Trojanowski.

PBA affects a diverse population of patients with neurologic disorders, including those with Alzheimer's, multiple sclerosis, Lou Gehrig's disease or ALS, Parkinson's, and those with neuronal damage following stroke or traumatic brain injury. While the underlying etiology varies from patient to patient, clinical presentations are characterized by uncontrolled emotional outbursts and inappropriate responses to various stimuli. Expert researchers and clinicians will present current information about the epidemiology, pathophysiology, differential diagnosis, and recommended clinical management of PBA as well as future developments in the treatment of PBA and emotional lability in patients with neurodegenerative diseases.

Pseudobulbar Affect: Emotional Lability in Neurodegenerative Diseases is sponsored by the University of Pennsylvania School of Medicine and supported by an unrestricted educational grant from AVANIR Pharmaceuticals. The University of Pennsylvania School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity has been approved for AMA PRA credit. In keeping with the University of Pennsylvania Health System mission

statement, CME is a vehicle for the institution's leaders in medicine and science to bring new discoveries, understanding, detection, treatment, and prevention of human disease to physicians in practice on a state, regional, national, and international level. While the majority of activities focus on clinical updates, CME also provides a forum for faculty to disseminate information on cutting-edge research, technology, treatment, and techniques to the medical community to improve patient care. The major goal of CME activities is to provide the physician participant with state-of-the-art information in all areas of medicine that is both relevant and essential to their practice.

AVANIR Pharmaceuticals is a drug discovery and development company focused on the development of treatments for neurodegenerative disorders and inflammatory diseases. Further information about AVANIR can be found at www.avanir.com.

The information contained in this press release, including any forward-looking statements contained herein, should be reviewed in conjunction with the company's most recent Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like “estimate,” “anticipate,” “believe,” “plan” or “expect”. The Company disclaims any intent or obligation to update these forward-looking statements.

CONTACT:
At Redington, Inc.:
Thomas Redington
203-222-7399
tredington@redingtoninc.com
or
At AVANIR Pharmaceuticals:
Patrice Saxon, Investor Relations
858-622-5202
psaxon@avanir.com